The stock of Cytosorbents Corp (NASDAQ:CTSO) is a huge mover today! The stock increased 5.16% or $0.33 on October 3, hitting $6.73. About 173,581 shares traded hands or 97.07% up from the average. Cytosorbents Corp (NASDAQ:CTSO) has risen 24.03% since February 29, 2016 and is uptrending. It has outperformed by 11.82% the S&P500.
The move comes after 6 months positive chart setup for the $176.15M company. It was reported on Oct, 4 by Barchart.com. We have $9.35 PT which if reached, will make NASDAQ:CTSO worth $68.70 million more.
Analysts await Cytosorbents Corp (NASDAQ:CTSO) to report earnings on November, 11. They expect $-0.11 earnings per share, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.12 actual earnings per share reported by Cytosorbents Corp for the previous quarter, Wall Street now forecasts -8.33% EPS growth.
Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage
Out of 2 analysts covering CytoSorbents (NASDAQ:CTSO), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytoSorbents has been the topic of 2 analyst reports since October 29, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by WBB Securities on Thursday, October 29. The stock of Cytosorbents Corp (NASDAQ:CTSO) has “Buy” rating given on Tuesday, May 24 by Maxim Group.
According to Zacks Investment Research, “CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company’s product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.”
Insitutional Activity: The institutional sentiment decreased to 0.79 in 2016 Q2. Its down 0.07, from 0.86 in 2016Q1. The ratio dropped, as 7 funds sold all Cytosorbents Corp shares owned while 7 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 1.36 million shares or 2.40% less from 1.40 million shares in 2016Q1.
Deutsche Comml Bank Ag has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). Raymond James And Associate last reported 0% of its portfolio in the stock. Tower Capital Limited Company (Trc) holds 694 shares or 0% of its portfolio. Northern Tru has 0% invested in the company for 23,709 shares. Blackrock Fund reported 53,915 shares or 0% of all its holdings. Fortaleza Asset Mgmt Inc, a Illinois-based fund reported 19,625 shares. Kcg Holding last reported 0% of its portfolio in the stock. Royal Bank Of Canada accumulated 800 shares or 0% of the stock. Barclays Plc has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). Geode Capital Mngmt Lc last reported 0% of its portfolio in the stock. Susquehanna Interest Grp Llp holds 0% or 22,848 shares in its portfolio. Blackrock Advsrs Ltd has 864 shares for 0% of their US portfolio. Skylands Cap Ltd Liability Corp owns 48,350 shares or 0.04% of their US portfolio. Morgan Stanley reported 2,130 shares or 0% of all its holdings. The Massachusetts-based State Street has invested 0% in Cytosorbents Corp (NASDAQ:CTSO).
Insider Transactions: Since June 7, 2016, the stock had 2 insider buys, and 0 sales for $39,090 net activity. 5,000 Cytosorbents Corp (NASDAQ:CTSO) shares with value of $24,450 were bought by Chan Phillip P.. $14,640 worth of shares were bought by BATOR MICHAEL G. on Tuesday, June 7.
More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Marketwatch.com which released: “Cytosorbents Corp.” on April 21, 2011, also Prnewswire.com with their article: “CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment …” published on September 07, 2016, Fool.com published: “Why Cytosorbents Corp Shares Burst Today” on April 01, 2015. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery …” published on September 12, 2016 as well as Quotes.Wsj.com‘s news article titled: “Cytosorbents Corp. CTSO (US: Nasdaq)” with publication date: July 07, 2012.
CTSO Company Profile
CytoSorbents Corporation, incorporated on April 25, 2002, is a critical care focused immunotherapy company. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.